Aim. To assess the results of the integrated treatment of women with recurrent chronic cystitis using the selective 3-adrenoreceptor (AR) agonist, mirabegron. Methods. The results of the treatment of women diagnosed with recurrent chronic cystitis in the urological clinic of KSMU were analyzed. The average age of patients was 31.53.4 years. To assess the effectiveness of integrated treatment, women with recurrent chronic cystitis were randomly divided into two groups: the first group (30 patients) who received antibiotic therapy in combination with the drug mirabegron at a dose of 50 mg once a day and the second (control) group (30 patients), who received antibiotic therapy taking into account their susceptibility. All patients underwent ultrasonography of the genitourinary system, urodynamic studies with assessment of the maximum urinary flow, average urinary flow, bacterial urine cultures. Results. Analysis of the research results showed a greater reduction in the number of urinations per day (up to 7 times) in the first group. The frequency of urinary urgency decreased in 82.6% of the first group patients compared to 64% of the second group (p 0.05). In the combination therapy versus control groups, there was reduced hospital stay by an average of 4 days (11.2 vs 15 days; p 0.05). On the 15th day of treatment, control cystoscopy revealed no changes in the bladder mucosa in all patients of the first group. Also, in the first group of patients, there was a greater improvement in urodynamic parameters compared to the control group (p 0.05). Conclusion. The selective 3-AR agonist mirabegron used in the integrated treatment of recurrent chronic cystitis increases the effectiveness of the therapy.
Background. Chronic cystitis is the dominating urinary tract disease. Due to its high prevalence among women, this issue remains topical in medicine. Aim. To evaluate the effectiveness of the sodium hyaluronate in the complex treatment of chronic recurrent cystitis. Material and methods. The research included 60 patients with a confirmed clinical diagnosis of chronic recurrent cystitis in the clinic of Kazan State Medical University for the period from July 2020 to July 2021. To evaluate the effectiveness of treatment, the patients were divided into groups using the copy-pair method. The first (main) group included 30 women receiving anti-inflammatory therapy and local treatment with collargol instillations. After that, the patients were prescribed the topical use of sodium hyaluronate: 40 mg (50 ml) once a week for 1 month. The second (control) group also included 30 patients who received only anti-inflammatory therapy and local treatment with collargol. The average age of the observed patients was 30.51.5 years: in the first group 31.11.5 years, in the second group 31.91.3 years. All patients underwent control cystoscopy, ultrasound and urodynamic examinations on the 15th and 30th day of treatment. The Welch's t-test, Fisher's test, analysis of variance with repeated observations were used as statistical data analysis methods. Results. Treatment was completed by all patients in both groups. The patients management showed a significant decrease in the number of urination (up to 6 times a day), and urgent uriesthesia was recorded in 86.6% of women in the main group compared to 60% in the control group (p 0.05). The control cystoscopy performed on the planned 15th day of treatment showed positive dynamics in the bladder mucosa recovery under the collargol influence. All patients of the first group had no changes in the mucous membrane of the bladder. There was a positive dynamics of urodynamic parameters in the first group compared to the control group. Conclusion. The sodium hyaluronate, which was included in the complex therapy of chronic recurrent cystitis, accelerates the process of the bladder mucosa regeneration after local treatment with collargol and reduces the time of its recovery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.